AVET
SpecialtyAVET is a specialty pharmaceutical company focused on Infectious Disease, Dermatology, Metabolic.
AVET's Key Drugs
AVET's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AVET's Recent FDA Approvals
New NDA/BLA approvals for AVET over the last two years — novel drugs only, excluding generics and label supplements.
AVET's Therapeutic Areas
AVET's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AVET's Top Competitors
AVET's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and KING PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AVET Pipeline Snapshot
Active clinical trials for AVET across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1957-10-08
- Latest
- 2025-03-31
- Applications
- 2